Stock 27F0 KALA BIO, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages KALA BIO, Inc. Deutsche Boerse AG

Equities

27F0

US4831192020

Real-time Estimate Tradegate
Other stock markets
 11:38:30 01/07/2024 BST 		5-day change 1st Jan Change
6.7 EUR +8.24% Intraday chart for KALA BIO, Inc. +30.50% -2.04%
06-28 KALA BIO, Inc. announced that it has received $12.499192 million in funding from Baker Bros. Advisors LP, ADAR1 Capital Management, LLC, SR One Capital Management, LP CI
06-27 Top Midday Gainers MT

Other languages

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Top Midday Gainers
Sector Update: Health Care Stocks Mixed Premarket Thursday
Kala Bio to Raise $12.5 Million in Private Placement; Shares Jump
KALA BIO, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
KALA BIO, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
KALA BIO, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
KALA BIO, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
KALA BIO, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
Kala Pharmaceuticals Changes Name to Kala Bio
Kala Pharmaceuticals, Inc. Announces Robert Paull Not Stands for Re-Election as A Director
Kala Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
Kala Pharmaceuticals Unit Secures $15 Million Grant from California Institute for Regenerative Medicine
Kala Pharmaceuticals, Inc. Appoints Francis Mah as Chief Medical Advisor
Kala Pharmaceutical to Proceed with Corneal Epithelial Defect Trial After Positive Safety Data in Cohort 1
Kala Pharmaceuticals, Inc. Announces Positive Safety Update from Cohort 1 of Chase Phase 2B Clinical Trial Evaluating KPI-012 in Patients with PCED
Kala Pharmaceuticals Files $350 Million Mixed Shelf, Files Shelf on Behalf of Selling Stockholders
Kala Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022
Kala Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022
Top Midday Gainers
Sector Update: Stocks Dragged Lower with Broader Friday Markets
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. KALA Stock
  4. 27F0 Stock
  5. News KALA BIO, Inc.
  6. Other languages